Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs
Value-based indication-specific and weighted-average pricing could help to align the value and price of new indications, thereby reducing expenditure on drugs with multiple indications.
Authors
- Daniel Tobias Michaeli (ORCID: https://orcid.org/0000-0003-2913-1867)
- Thomas Michaeli
Institutions
- University of Wuppertal (DE)
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- National Center for Tumor Diseases (DE)
- University Medical Centre Mannheim (DE)
Publication Details
- Journal
- PharmacoEconomics
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1007/s40273-024-01448-x
- Citations
- 2
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 2.26
Funders
- Bergische Universität Wuppertal
- Universitätsklinikum Heidelberg